Clinical Trials Browser

Phase 3 × INDUSTRY × Androgen Antagonists × Clear all

NCT06952803 2026-04-21

EvoPAR-PR02

Phase 3 Recruiting

Prostatic Neoplasms

NCT04076059 2026-04-17

China ARCHES

Phase 3 Active not recruiting

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer

NCT02489318 2026-04-13

TITAN

Phase 3 Active not recruiting

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT03767244 2026-04-13

PROTEUS

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04191096 2026-03-20

KEYNOTE-991

Phase 3 Active not recruiting

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05884398 2026-03-12

LIBERTAS

Phase 3 Active not recruiting

Metastatic Castrate-sensitive Prostate Cancer

NCT04736199 2026-02-27

ARANOTE

Phase 3 Completed

669 enrolled 16 charts

Prostatic Neoplasms

NCT02799602 2025-12-04

ARASENS

Phase 3 Completed

1,306 enrolled 25 charts 4 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT04934722 2025-10-01

KEYNOTE-991

Phase 3 Completed

186 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT01715285 2025-02-04

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Phase 3 Completed

1,209 enrolled 16 charts 1 FDA

Prostatic Neoplasms

NCT00242567 2014-05-07

Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer

Phase 3 Completed

522 enrolled 8 charts

Prostatic Neoplasms